J&J sees AI halving the time to generate drug development leads
· Source: manufacturing.economictimes.indiatimes.com
In short
Johnson & Johnson is leveraging artificial intelligence to cut lead optimisation time in drug development by half, according to CIO Jim Swanson. The company has already accelerated development for two compounds in oncology and immunology, and is applying AI across manufacturing, medical devices, and regulatory documentation. Swanson emphasized AI as an augmenting tool rather than a replacement for employees.
Read Original Article — Read the full article on the publisher’s site.
In the issue of week 18, 2026: Agentic AI and Physical Automation Drive Supply Chain Breakthroughs
Tags: AI, drug development, pharmaceutical, supply chain, manufacturing, clinical trials